Treatment Persistence in Rheumatoid Arthritis Before and After Etanercept Biosimilar Introduction: A Nationwide Australian Real-World Study
This large, population-based study found no significant difference in treatment persistence following the introduction of the etanercept biosimilar in Australia. These findings support the real-world integration of biosimilars into routine care. Further research should include direct comparative analyses of originator and biosimilars to inform long-term treatment strategies, clinician confidence, and sustainable healthcare policy.
Authors
- Chin Hang Yiu (ORCID: https://orcid.org/0000-0001-7758-6087)
- Jacques Raubenheimer (ORCID: https://orcid.org/0000-0003-3907-304X)
- Richard Osborne Day (ORCID: https://orcid.org/0000-0002-6045-6937)
- Christine Y. Lu (ORCID: https://orcid.org/0000-0002-7550-6837)
- Bella D. Ianni
Institutions
- The University of Sydney (AU)
- Royal North Shore Hospital (AU)
- Northern Sydney Local Health District (AU)
- St Vincent's Clinic (AU)
Publication Details
- Journal
- Pharmaceutical Medicine
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1007/s40290-025-00577-8
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Sydney